Ineffectiveness Causes Asundexian Phase 3 AF Study to Be Aborted.

Published Date: 21 Nov 2023

Due to its lower efficacy compared to apixaban in preventing stroke and systemic embolism in patients with AF, the phase 3 OCEANIC-AF trial of the factor XI inhibitor asundexian (Bayer) was terminated early.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot